CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Immunopharmacologic Monitoring of Therapeutic Serum Antibodies

Policy governing coverage of serum drug level and anti-drug antibody testing (therapeutic drug monitoring) for biologic therapies, particularly anti-TNF agents and select biologics, with specific indications for inflammatory bowel disease and noncoverage for other inflammatory conditions; applies to Blue Cross Blue Shield - Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyImmunopharmacologic Monitoring of Therapeutic Serum Antibodies

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionDocument testing indication: obtain drug/antibody concentrations at end of induction, at least once during maintenance, or for confirmed loss of response in IBD.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7/1/2023Effective date adopted

3-7IFX trough target (CD)

5-10IFX trough target (UC)

34%Cost reduction

458Trial participants

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Therapeutic Drug Monitoring

Anti-TNF testing — IBD

Covered when ALL of the following are met for individuals with inflammatory bowel disease receiving anti-TNF therapy:

Anti-TNF IBD TDM covered: Drug and/or antibody concentration testing for anti-TNF therapies is covered when performed: (a) at the end of induction for all anti-TNFs; (b) at least once during maintenance therapy; (c) at the end of induction in primary non-responders; and (d) in patients with confirmed secondary loss of response.

from policy Indications and/or Limitations of Coverage

Vedolizumab/Ustekinumab testing — IBD

Covered when ALL of the following are met for individuals with inflammatory bowel disease receiving vedolizumab or ustekinumab:

Vedolizumab/Ustekinumab IBD TDM covered: Drug and/or antibody concentration testing for vedolizumab or ustekinumab is covered in non-responders at the end of induction and in patients with confirmed secondary loss of response.

from policy Indications and/or Limitations of Coverage

Appropriate testing scenarios (Consensus statements)

Guideline-based scenarios where ordering drug/antibody concentration testing is appropriate (consensus statements and thresholds):

Anti-TNF testing scenarios: It is appropriate to order drug/antibody concentration testing for anti-TNFs: in responders at the end of induction; at least once during maintenance; at the end of induction for primary non-responders; and for patients with confirmed secondary loss of response.see thresholds module

consensus agreement 92-100% across panel (Papamichael et al., 2019)

Vedolizumab testing scenarios: For vedolizumab, testing is appropriate in non-responders at the end of induction and in patients with confirmed secondary loss of response; routine testing in responders or for proactive maintenance monitoring did not reach consensus and specific numeric thresholds are not recommended.no specific thresholds recommended

consensus mixed; evidence insufficient for numeric targets

Ustekinumab testing scenarios:

Concentration targets and evidence statements

Guidance on drug concentration targets where provided

Golimumab concentrations: Minimum golimumab drug concentration at induction (week 6) should be at least 2.5 μg/mL; during maintenance, the minimal trough concentration for patients in remission should be greater than 1 μg/mL.week6 >= 2.5 μg/mL; maintenance trough >1 μg/mL

consensus statement (Papamichael et al., 2019)

Infliximab and other anti-TNF targets (reference): Consensus statements provide agent-specific trough recommendations for anti-TNFs (e.g., infliximab minimal post-induction and maintenance trough >3 μg/mL; adalimumab minimal week 4 and maintenance >5 μg/mL; certolizumab higher week-6 and maintenance targets). These agent-specific thresholds are summarized in the thresholds module.see agent-specific thresholds in thresholds module

see document Table 4–6 and consensus statements

Vedolizumab and Ustekinumab monitoring:

Testing for serum drug concentrations and anti-drug antibodies to anti-TNF agents in patients who do not have inflammatory bowel disease (including spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis) does not meet coverage criteria. The policy explicitly excludes drug- and antibody-level testing for anti-TNF therapies in non‑IBD indications and such requests may be denied when submitted for those conditions.

Measurement of serum drug levels and/or antibodies to the following biologics in an outpatient setting for reasons other than the specified IBD indications does not meet coverage criteria: adalimumab, certolizumab, etanercept, golimumab, infliximab (and listed infliximab biosimilars), rituximab, ustekinumab, and vedolizumab.

The NICE guidance notes that commercially available ELISA kits for measuring TNF‑alpha inhibitor drug levels and anti‑drug antibodies "show promise" but that there is insufficient evidence to recommend routine adoption. NICE recommends that ELISA testing be used in research or data-collection settings while additional evidence on clinical effectiveness is developed.

For vedolizumab and ustekinumab, current evidence is described as emerging but insufficient to define specific numeric induction or maintenance concentration targets. The guidance therefore supports confirming a detectable drug level when testing but does not endorse particular numeric thresholds for these agents.

Use of serum drug level and anti‑drug antibody testing for the listed biologics outside the IBD indications specified in this policy is considered not medically necessary and does not meet coverage criteria due to lack of supporting evidence of benefit.

Major gastroenterology guideline panels do not endorse routine proactive therapeutic drug monitoring for all unselected patients in remission. The AGA suggests reactive TDM for adults with active IBD treated with anti‑TNF agents and makes no recommendation for routine proactive monitoring in quiescent disease; the ACG likewise advises consideration of TDM when active disease, nonresponse, or loss of response is documented and notes insufficient evidence to support proactive monitoring for all patients in remission.

Agent-specific Concentration Targets and Coding-related Key Values

Infliximab trough concentration — induction & maintenance

Induction-associated mucosal healing thresholdTrough concentration ≈ ≥2.1 µg/mL associated with mucosal healing (LFA study).

Maintenance trough associated with remissionMaintenance trough >2 µg/mL associated with greater probability of clinical remission and mucosal healing (systematic review/meta-analysis).

Assay agreement noteLFA agreed well with ELISA for infliximab quantification (correlation coefficient 0.95 during induction).

Proactive infliximab trough targets

Crohn's disease target (proactive)IFX trough target 3–7 µg/mL when using a proactive TDM regimen.

Ulcerative colitis target (proactive)

Provider Actions, Documentation, and Authorization Notes

Documentation Required

Coverage limited to IBD indications

Coverage of therapeutic drug and anti-drug antibody concentration testing is limited to inflammatory bowel disease (IBD) indications. For IBD patients, testing for anti-TNF agents MEETS COVERAGE CRITERIA when performed in the following situations: at the end of induction for all anti-TNFs; at least once during maintenance therapy; at the end of induction in primary non-responders; and in patients with confirmed secondary loss of response. For vedolizumab or ustekinumab in IBD, testing MEETS COVERAGE CRITERIA for non-responders at the end of induction and for patients with confirmed secondary loss of response.

Coverage limited to IBD indications: drug and/or antibody concentration testing allowed for anti-TNF agents and for vedolizumab/ustekinumab only in specified IBD scenarios.

Denial Risk

Non-IBD anti-TNF testing not covered

Testing for drug and/or antibody concentrations for anti-TNF therapies in individuals without inflammatory bowel disease (including spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis) DOES NOT MEET COVERAGE CRITERIA. Additionally, measurement of serum drug levels and/or antibodies to listed biologics (adalimumab, certolizumab, etanercept, golimumab, infliximab and biosimilars, rituximab, ustekinumab, vedolizumab) for any other outpatient reason DOES NOT MEET COVERAGE CRITERIA.

Background and Scope

TNF inhibitors (infliximab, adalimumab, certolizumab, golimumab, etanercept) and other biologic agents such as vedolizumab and ustekinumab are used to treat immune‑mediated inflammatory diseases. Development of anti‑drug antibodies and low drug concentrations are recognized contributors to secondary loss of response. This policy applies specifically to measurement of serum drug levels and anti‑drug antibodies for the listed agents and limits coverage primarily to therapeutic drug monitoring in inflammatory bowel disease; testing for the same agents outside the stated IBD indications is not covered.

Definitions and Terminology

Anti-drug antibody status (ADAbs)

DefinitionAnti-drug antibody status (ADAbs) — presence of antibodies directed against a biologic therapy.

Abbreviations exampleIncludes specific antibody terms such as ATI (antibodies-to-infliximab) and ATA (antibodies-to-adalimumab).

Clinical implicationHigh-titer ADAbs to infliximab may require change of therapy; low-level antibodies may sometimes be overcome (see assay-specific cutoffs).

Therapeutic drug monitoring (TDM)

DefinitionTherapeutic drug monitoring (TDM) — measurement of serum drug concentrations and anti-drug antibodies to guide dosing and management.

ScopeApplies to monitoring of biologic therapies such as anti-TNFs and selected other agents in IBD management.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyImmunopharmacologic Monitoring of Therapeutic Serum Antibodies

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionDocument testing indication: obtain drug/antibody concentrations at end of induction, at least once during maintenance, or for confirmed loss of response in IBD.

SourceLink

On This Page

For ustekinumab, testing is appropriate in non-responders at the end of induction (e.g., ~8 weeks) and in patients with confirmed secondary loss of response; routine proactive monitoring in responders or maintenance had lower consensus and no specific numeric thresholds were endorsed beyond detectability.

no specific thresholds recommended except detectability

consensus mixed; see Papamichael et al., 2019

For vedolizumab and ustekinumab, current data are emerging but insufficient to support specific numeric induction or maintenance concentration targets beyond confirming detectable drug.

Do not use numeric targets for these agents based on current evidence in this document (Papamichael et al., 2019)

IFX trough target 5–10 µg/mL when using a proactive TDM regimen.

Proactive regimen timingMeasure trough before fourth infusion and subsequently every two infusions in the described proactive protocol.

Agent-specific trough concentration thresholds

Infliximab thresholdsMinimal trough >3 µg/mL post-induction and during maintenance for patients in remission; concentrations >7 µg/mL associated with increased likelihood of mucosal healing.

Adalimumab thresholdsMinimum concentration at week 4 ≥5 µg/mL; maintenance trough >5 µg/mL for remission; >7 µg/mL associated with mucosal healing.

Certolizumab pegol thresholdsMinimum at week 6 >32 µg/mL; maintenance trough for remission ≈15 µg/mL.

Golimumab thresholdsWeek 6 minimum ≥2.5 µg/mL; maintenance trough >1 µg/mL for patients in remission.

Golimumab minimum concentration (week 6)

Golimumab week 6 minimumMinimum drug concentration at week 6 should be at least 2.5 µg/mL.

Consensus strengthRecommendation reached consensus (92%, 11/12 panelists) in the referenced statement.

Golimumab maintenance trough in remission

Golimumab maintenance trough for remissionDuring maintenance, minimum trough concentration for golimumab in patients in remission should be >1 µg/mL.

Consensus strengthRecommendation reached consensus (92%, 11/12 panelists) in the referenced statement.

Non-IBD anti-TNF testing not covered; listed outpatient TDM tests not covered.

Prior Authorization

Prior authorization not specified

No payer-specific prior authorization requirement is specified in this policy section. Testing is driven by clinical guidelines and situational documentation described below (reactive TDM for active IBD, consideration of TDM in specific other circumstances). If government policies (LCDs/NCDs) apply, those take precedence.

Prior authorization not specified — guideline-driven testing.
If conflict with government policy, government policy governs.

Note

Prior authorization note

Operational note: Effective date 7/1/2023 — policy adopted Avalon recommendation. No explicit CPT/HCPCS codes or payer-level prior authorization triggers are specified in this section.

Effective date: 7/1/2023.
Policy adopted Avalon recommendation.
No explicit CPT/HCPCS or prior authorization requirements present.

Documentation Required

Provider documentation and management guidance

Documentation expectations and actionable provider steps: document indication of IBD and the clinical scenario justifying testing (end of induction, at least once during maintenance, primary non-response at end of induction, or confirmed secondary loss of response). For vedolizumab/ustekinumab, document non-response at end of induction or confirmed secondary loss of response. Use therapeutic drug monitoring results to guide management decisions (escalation, dose intensification, or switching therapies) consistent with evidence and consensus statements.

IBD testing documentation: support testing at end of induction, at least once during maintenance, for primary non-response at end of induction, and for confirmed secondary loss of response.
Vedolizumab/ustekinumab documentation: non-response at end of induction or confirmed secondary loss of response required.

Note

TDM-informed management

Therapeutic drug monitoring (TDM) can inform management: algorithms based on drug and antibody levels may guide dose intensification, switching therapies, or other interventions. Studies have shown that TDM-informed individualized management can affect treatment decisions, may increase appropriate changes in management, and can impact costs compared with blind dose escalation.

TDM-informed management: use drug and antibody concentrations to guide escalation, dose intensification, or switching therapies.
Evidence shows algorithmic TDM can reduce costs vs routine dose escalation and may improve decision-making.

Note

Evidence summaries and guideline context

Evidence context: literature and guideline summaries discuss proactive versus reactive TDM strategies. Guideline bodies (AGA, ACG, consensus statements, and NICE) generally recommend reactive TDM for active IBD and note uncertainty or conditional recommendations regarding routine proactive TDM in quiescent disease. Some studies and economic models report potential benefits or marginal cost-effectiveness for proactive strategies under certain assumptions, but these do not translate into universal payer-level operational triggers.

Evidence summaries discuss proactive vs reactive TDM and potential cost-effectiveness differences.
Cited literature discusses proactive vs reactive TDM and individualized therapy versus dose intensification.

PurposeUsed to inform dose intensification, switching therapies, or other management decisions based on drug and antibody levels.

Proactive therapeutic drug monitoring (pTDM)

DefinitionProactive TDM — scheduled monitoring of serum drug levels and anti-drug antibodies (e.g., after induction and at least once during maintenance) to guide dosing adjustments before clinical failure.

AppropriatenessConsensus statement found proactive TDM appropriate after induction and at least once during maintenance for anti-TNF therapies (not uniformly for other biologics).

Example protocolIn one proactive regimen, measure before fourth infusion and then every two infusions to target specific trough ranges.

Reactive therapeutic drug monitoring

DefinitionReactive TDM — measurement of drug levels and anti-drug antibodies in response to clinical relapse or confirmed loss of response to determine the cause and guide therapy changes.

Consensus recommendationReactive TDM was considered appropriate for all agents for primary non-response and secondary loss of response per the consensus statement.

Clinical useAids decisions such as dose intensification, addition of immunomodulator, or switching biologic based on drug and antibody status.

Detectable drug

DefinitionDetectable drug — confirmation that a biologic agent is present at measurable concentration; for some agents (vedolizumab, ustekinumab) guidance currently recommends only confirming detectability rather than numeric targets.

ContextEvidence for specific numeric induction or maintenance targets is insufficient for vedolizumab and ustekinumab beyond confirming detectable drug.

ImplicationDetectable drug may be used to distinguish pharmacokinetic failure from immunologic/biologic nonresponse when guiding management.

Laboratory-developed test (LDT) and CLIA note

DefinitionLaboratory-developed test (LDT) — a test developed and performed in-house by a laboratory.

Regulatory statusLDTs are regulated under CLIA as high-complexity tests and are not currently FDA-cleared or -approved for clinical use; laboratories must validate and perform them in-house.

Operational noteMany labs developing specific assays for drug level or antibody testing must validate these LDTs per CLIA requirements before clinical use.